AI Stock Analysis - Apellis Pharmaceuticals (APLS)
Analysis generated January 22, 2026.
Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds. The company emphasizes targeting the complement system, a part of the immune system involved in inflammation and cell destruction. Apellis's lead product, Pegcetacoplan, is advancing its clinical trials and pipeline, aiming to address serious unmet medical needs across various medical conditions.
Stock Alerts - Apellis Pharmaceuticals (APLS)
 |
Apellis Pharmaceuticals | January 28 Price is up by 6.7% in the last 24h. |
|
Apellis Pharmaceuticals | January 27 Business Outlook among employees is up by 11.4% over the last month. |
|
Apellis Pharmaceuticals | January 27 Employee Rating is up by 2.9% over the last month. |
|
Apellis Pharmaceuticals | January 24 Insider Alert: Baumal Caroline is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Apellis Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 29 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 20,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,690 | Sign up | Sign up | Sign up |
| X Followers | 1,681 | Sign up | Sign up | Sign up |
| X Mentions | 9 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 830 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 814 | Sign up | Sign up | Sign up |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
| Price | $22.05 |
| Target Price | Sign up |
| Volume | 1,340,000 |
| Market Cap | $2.82B |
| Year Range | $17.31 - $30.05 |
| Dividend Yield | 0% |
| PE Ratio | 63.74 |
| Analyst Rating | 61% buy |
| Earnings Date | February 24 '26 |
| Industry | Biotechnology |
In the news
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial ResultsFebruary 10 - GlobeNewswire |
|
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning?January 17 - Yahoo Entertainment |
|
 |
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 12 - SeekingAlpha |
|
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 12 - SeekingAlpha |
Age-Related Macular Degeneration Market to Reach US$ 19.72 Billion by 2032 Driven by Aging Population, Rising Chronic Disease Burden, and Advances in Anti-VEGF Therapies | Astute AnalyticaFebruary 3 - GlobeNewswire |
|
EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPSJanuary 26 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 459M | 25M | 434M | 216M | 228M | 1.670 |
| Q2 '25 | 178M | 14M | 164M | -42M | -30M | -0.330 |
| Q1 '25 | 167M | 34M | 132M | -92M | -80M | -0.740 |
| Q4 '24 | 213M | 41M | 172M | -36M | -24M | -0.290 |
| Q3 '24 | 197M | 34M | 163M | -57M | -44M | -0.462 |
Insider Transactions View All
| Watson David O. filed to sell 88,531 shares at $21.8. January 23 '26 |
| Nicholson Nur filed to sell 71,118 shares at $21.8. January 23 '26 |
| Deschatelets Pascal filed to sell 1,151,382 shares at $21.8. January 23 '26 |
| DeLong Mark Jeffrey filed to sell 78,353 shares at $21.8. January 23 '26 |
| Chopas James George filed to sell 49,805 shares at $21.8. January 23 '26 |
Similar companies
Read more about Apellis Pharmaceuticals (APLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Apellis Pharmaceuticals
The Market Cap of Apellis Pharmaceuticals is $2.82B.
As of today, Apellis Pharmaceuticals' PE (Price to Earnings) ratio is 63.74.
Apellis Pharmaceuticals will report its next earnings on February 24 '26.
Currently, the price of one share of Apellis Pharmaceuticals stock is $22.05.
The APLS stock price chart above provides a comprehensive visual representation of Apellis Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Apellis Pharmaceuticals shares. Our platform offers an up-to-date APLS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Apellis Pharmaceuticals (APLS) does not offer dividends to its shareholders. Investors interested in Apellis Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Apellis Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
